Outset Medical, Inc. (NASDAQ:OM – Get Free Report) has been assigned an average recommendation of “Hold” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $4.64.
A number of research firms have recently issued reports on OM. TD Cowen cut their target price on shares of Outset Medical from $9.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Royal Bank of Canada cut shares of Outset Medical from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $6.00 to $3.00 in a research report on Thursday, August 8th.
Check Out Our Latest Report on OM
Institutional Inflows and Outflows
Outset Medical Stock Down 6.7 %
NASDAQ OM opened at $0.63 on Friday. Outset Medical has a twelve month low of $0.44 and a twelve month high of $10.77. The stock has a market cap of $32.91 million, a PE ratio of -0.19 and a beta of 1.92. The firm has a 50-day simple moving average of $1.28 and a 200 day simple moving average of $2.58. The company has a debt-to-equity ratio of 2.87, a quick ratio of 5.38 and a current ratio of 6.80.
Outset Medical (NASDAQ:OM – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.07). The business had revenue of $27.39 million for the quarter, compared to the consensus estimate of $31.19 million. Outset Medical had a negative return on equity of 143.52% and a negative net margin of 136.72%. During the same period in the previous year, the business posted ($0.90) earnings per share. On average, research analysts forecast that Outset Medical will post -2.52 EPS for the current year.
Outset Medical Company Profile
Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
See Also
- Five stocks we like better than Outset Medical
- The 3 Best Retail Stocks to Shop for in August
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Basic Materials Stocks Investing
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.